Cavion is a clinical-stage pharmaceutical company developing first-in-class therapies to restore the brain’s natural rhythms by modulating overactive T-type calcium channels for a range of neurological and rare genetic diseases.  Cavion’s mission is to combine our deep understanding of T-type calcium channel (Cav3) biology with superior chemistry and clinical research innovation and expertise to provide therapeutics that will improve people’s lives.

Cavion’s pipeline is comprised of best-in-class Cav3 modulators obtained from both internal drug discovery and in-licensing efforts.

Cavion is pioneering new treatments to significantly improve the lives of people with movement disorders and other neurological diseases. As we work to bring these therapies to market, Cavion will use innovation to improve all aspects of trial conduct and patient engagement. Our clinical trials will integrate unobtrusive biometric monitoring devices that deliver meaningful data while causing less inconvenience for participants.